CUFinder

Mauro Loi

About Mauro Loi

Mauro Loi, With an exceptional h-index of 25 and a recent h-index of 23 (since 2020), a distinguished researcher at Università degli Studi di Firenze, specializes in the field of radiotherapy, oncology, stereotactic radiotherapy.

His recent articles reflect a diverse array of research interests and contributions to the field:

142 Hypofractionated re-irradiation with Cyberknife for locoregionally recurrent head and neck cancer: a single-center study.

PO-1459 Stereotactic salvage radiotherapy for prostate red relapse, early analysis from a prospective trial

Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: a randomized phase II trial (ARTO)

PO-1372 Stereotactic Radiotherapy In Pancreatic Cancer: An Update Of A National Survey

Radiomic Analysis for Human Papillomavirus Assessment in Oropharyngeal Carcinoma: Lessons and Pitfalls for the Next Future

PO-1329 Survival and prognostic factors of ultra-central tumors treated with stereotactic body radiotherapy

PO-1184 Hypofractionated re-irradiation for locoregionally recurrent head and neck cancer

Stereotactic reirradiation with CyberknifeR for locally recurrent prostate cancer, long-term toxicity and clinical outcomes from a monocentric cohort

Mauro Loi Information

University

Position

Radiotherapy Department Italy

Citations(all)

1694

Citations(since 2020)

1481

Cited By

654

hIndex(all)

25

hIndex(since 2020)

23

i10Index(all)

58

i10Index(since 2020)

51

Email

University Profile Page

Google Scholar

Mauro Loi Skills & Research Interests

radiotherapy

oncology

stereotactic radiotherapy

Top articles of Mauro Loi

142 Hypofractionated re-irradiation with Cyberknife for locoregionally recurrent head and neck cancer: a single-center study.

Radiotherapy and Oncology

2024/3/1

Mauro Loi
Mauro Loi

H-Index: 13

Pierluigi Bonomo
Pierluigi Bonomo

H-Index: 10

Lorenzo Livi
Lorenzo Livi

H-Index: 18

PO-1459 Stereotactic salvage radiotherapy for prostate red relapse, early analysis from a prospective trial

Radiotherapy and Oncology

2023/5/1

Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: a randomized phase II trial (ARTO)

Journal of Clinical Oncology

2023/12/20

Lorenzo Livi
Lorenzo Livi

H-Index: 18

Fabio Arcidiacono
Fabio Arcidiacono

H-Index: 0

Mauro Loi
Mauro Loi

H-Index: 13

Pierluigi Bonomo
Pierluigi Bonomo

H-Index: 10

Monica Mangoni
Monica Mangoni

H-Index: 19

PO-1372 Stereotactic Radiotherapy In Pancreatic Cancer: An Update Of A National Survey

Radiotherapy and Oncology

2023/5/1

Radiomic Analysis for Human Papillomavirus Assessment in Oropharyngeal Carcinoma: Lessons and Pitfalls for the Next Future

2023/12/4

Mauro Loi
Mauro Loi

H-Index: 13

Pierluigi Bonomo
Pierluigi Bonomo

H-Index: 10

Lorenzo Livi
Lorenzo Livi

H-Index: 18

PO-1329 Survival and prognostic factors of ultra-central tumors treated with stereotactic body radiotherapy

Radiotherapy and Oncology

2023/5/1

PO-1184 Hypofractionated re-irradiation for locoregionally recurrent head and neck cancer

Radiotherapy and Oncology

2023/5/1

Stereotactic reirradiation with CyberknifeR for locally recurrent prostate cancer, long-term toxicity and clinical outcomes from a monocentric cohort

La radiologia medica

2023/12

Mauro Loi
Mauro Loi

H-Index: 13

Pierluigi Bonomo
Pierluigi Bonomo

H-Index: 10

Lorenzo Livi
Lorenzo Livi

H-Index: 18

PO-1381 Management of esophageal cancers. Survey by the AIRO Gastrointestinal Tumors Study Group

Radiotherapy and Oncology

2023/5/1

Modulation of tumor-associated macrophage activity with radiation therapy: a systematic review

2023/12

Monica Mangoni
Monica Mangoni

H-Index: 19

Mauro Loi
Mauro Loi

H-Index: 13

Lorenzo Livi
Lorenzo Livi

H-Index: 18

PD-0576 Stereotactic reirradiation for locally recurrent prostate cancer after definitive radiotherapy

Radiotherapy and Oncology

2023/5/1

PO-1354 Pattern of failure after stereotactic body radiotherapy to liver metastases: impact of local control

Radiotherapy and Oncology

2023/5/1

Pattern of recurrence after stereotactic body radiotherapy for para-aortic oligo-recurrent prostate cancer, a multicentric analysis

La radiologia medica

2023/11

Federico Colombo
Federico Colombo

H-Index: 4

Mauro Loi
Mauro Loi

H-Index: 13

Lorenzo Livi
Lorenzo Livi

H-Index: 18

PO-1556 Pattern Of Disease Progression Following Locoregional Treatment In Oligometastatic Sts Patients

Radiotherapy and Oncology

2023/5/1

1779P PSMA guided approach for bIoCHEmical relapse after prostatectomy-PSICHE trial

Annals of Oncology

2023/10/1

Ultra-Central Tumors Treated with Stereotactic Body Radiotherapy: Clinical Outcome and Prognostic Factors

International Journal of Radiation Oncology, Biology, Physics

2023/10/1

Early biochemical outcomes following PSMA guided approach for bIoCHEmical relapse after prostatectomy-PSICHE trial (NCT05022914): preliminary results

Clinical & experimental metastasis

2023/4

Mauro Loi
Mauro Loi

H-Index: 13

Lorenzo Livi
Lorenzo Livi

H-Index: 18

Systemic inflammation and lung cancer: is it a real paradigm? Prognostic value of inflammatory indexes in patients with resected non-small-cell lung cancer

Cancers

2023/3/20

Mauro Loi
Mauro Loi

H-Index: 13

Radiobiology of the Skin and Non-Melanoma Skin Neoplasms

2023/3/16

Monica Mangoni
Monica Mangoni

H-Index: 19

Mauro Loi
Mauro Loi

H-Index: 13

Lorenzo Livi
Lorenzo Livi

H-Index: 18

Preoperative Radiotherapy of Soft Tissue Sarcoma with Simultaneous Integrated Boost: A Phase II Study

International Journal of Radiation Oncology, Biology, Physics

2023/10/1

See List of Professors in Mauro Loi University(Università degli Studi di Firenze)